Similar Papers

Paper Title
Journal
Date
Author
Second-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia with Additional Chromosomal Abnormalities
Naoto Takahashi ... Itaru Matsumura
Blood | VOL. 134
Naoto Takahashi, et. al.Naoto Takahashi ... Itaru Matsumura
13 Nov 2019
Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial
Chikashi Yoshida ...
Blood | VOL. 138
Chikashi Yoshida, et. al.Chikashi Yoshida ...
05 Nov 2021
Efficacy and Safety of Tyrosine Kinase Inhibitors for Treatment of Newly Diagnosed Chronic Myeloid Leukemia: Results Using Data Obtained with the New Target System from the Japanese Registry
Naoto Takahashi ... Koichi Akashi
Blood | VOL. 132
Naoto Takahashi, et. al.Naoto Takahashi ... Koichi Akashi
29 Nov 2018
Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial
...
Blood | VOL. 138
, et. al. ...
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface.
Zohreh Mansoori Moghadam ... Philipp Henneke
Blood | VOL. -
Zohreh Mansoori Moghadam, et. al.Zohreh Mansoori Moghadam ... Philipp Henneke
03 Feb 2025
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.
Michael C Zaiken ... Bruce R Blazar
Blood | VOL. -
Michael C Zaiken, et. al.Michael C Zaiken ... Bruce R Blazar
03 Feb 2025
How I approach pharmacological thromboprophylaxis in children.
Anthony A Sochet ... Neil A Goldenberg
Blood | VOL. -
Anthony A Sochet, et. al.Anthony A Sochet ... Neil A Goldenberg
03 Feb 2025
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.